ProclaRx, based in Athens OH, is a pre-clinical stage biopharmaceutical company with the exclusive worldwide rights to develop and commercialize our first-in-class anti-bacterial biofilm IP technology. Our labs and regulatory and clinical partners optimize our commercialization pathways while keeping costs low.
ProclaRx pursuit of
Chairman of the Board
Nick Henderson is Managing Partner of Applied Bio Ventures. Prior to that, he was CEO of Applied Biomolecular Technologies, a technology development company focused on commercializing
Chief Executive Officer
Joseph D. Kittle Jr., Ph.D. has over 20 years of experience in the world of biotechnology. Dr. Kittle has expertise in the development of products and services in the areas
Chief Scientific Officer
Tom Zupancic, Ph.D. is a molecular biologist with more than 25 years of experience in the design and execution of applied biotechnology research projects. He has extensive hands-on experience designing and leading product development programs in Biotechnology and Biopharmaceutical development. Specific projects span a broad range of scientific and technology areas
Research and Development
Rich Brody is a biochemist with more than 30 years of experience directing laboratory programs in protein biochemistry. He directed contract research programs at Battelle, where completing projects on time and on
Chief Operating Officer
Doug Martin brings more than 20 years of extensive legal and business experience to his new executive role at ProclaRx. As COO, Mr. Martin will be responsible for the strategic planning, compliance, and coordination of R&D resources. He will report directly to Nick Henderson, Chairman of the Board at ProclaRx.